The purpose of this award is to advance the development of isola's nebulization therapy, a medical countermeasure designed to prevent and treat pulmonary foam the inhalation of chemical agents causes.
Active Definitive Contract Awarded Last action
- Contract number
- 75A50126C00005
- Awardee
-
Isola Therapeutics Inc. UEI M3QDM72NME75
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $7,485,417
Award facts
- Opportunity
-
- EZBAA22100SOL00003 Solicitation number
- Contract value 100% obligated
- $7,485,416.99 Current and potential, with all options
- Completion date 21% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Minneapolis, MN 55410, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR), awarded a definitive firm fixed-price contract to Isola Therapeutics Inc. (UEI: M3QDM72NME75) on May 1, 2026, with a ceiling value of $7.49 million. The contract, which operates under no set-aside designation, will be performed in Minneapolis, Minnesota, and has an ultimate completion date of October 31, 2028. The award supports the advancement of Isola's nebulization therapy, a medical countermeasure designed to prevent and treat pulmonary foam resulting from inhalation of chemical agents.
This contract reflects ASPR's mission to strengthen national preparedness and response capabilities for public health emergencies and chemical threats. Nebulization therapy represents an important therapeutic approach for addressing chemical exposure injuries, particularly for agents known to cause pulmonary complications. The firm fixed-price structure provides cost certainty for the government while establishing clear performance expectations for the contractor through the nearly two-year development period.
Quick answers
Who was awarded contract 75A50126C00005?
75A50126C00005 was awarded to Isola Therapeutics Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on May 1, 2026.
How much is contract 75A50126C00005 worth?
The government has obligated $7,485,417 on 75A50126C00005.
Was contract 75A50126C00005 competed?
The extent of competition for 75A50126C00005 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award